Drug Importation
			Blog					
			
		Learn How Drug Price Controls Hurt Patients
Big Pharma Is Not Gouging Americans nor Driving Up Healthcare Costs
			Whether it is Sanders vilifying pharmaceutical companies or Trump’s emphasis on imposing price controls, they both allege that drug spending is a primary driver of the nation’s rising healthcare costs. Even a cursory look at the data demonstrates their focus is misplaced. Let’s start with the national health expenditure data ...		
					
					
			
																				
			Wayne Winegarden		
				
																						
			October 8, 2025		
				
					
			Commentary				
			
		Cheap Drugs from Canada Can’t Make America Healthy
			The U.S. Food and Drug Administration just announced plans to help states and Indian tribes purchase certain prescription drugs from Canada, where brand-name medicines tend to be cheaper because the government caps their price. The new guidance is part of a larger Trump administration effort to cut drug prices for ...		
					
					
			
																				
			Sally C. Pipes		
				
																						
			July 11, 2025		
				
					
			Blog				
			
		The 340B Discounts Hospitals Receive Will Often Exceed Total Drug Prices in Europe
			Table 1: PBM Fees and Rebates Can Exceed International Prescription Medicine Prices by As Much As 900% I previously highlighted how estimated rebates and fees PBMs receive for 10 commonly used brand medicines far exceed the total prices of those medicines in eight OECD countries (see Table 1). For example, ...		
					
					
			
																				
			Wayne Winegarden		
				
																						
			June 16, 2025		
				
					
			Drug Importation				
			
		Listen to Sally Pipes on “Free the Economy” podcast
			Listen to PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes discuss her new book The World’s Medicine Chest (Encounter Books) on the Free the Economy podcast from the Competitive Enterprise Institute. Click here to listen		
					
					
			
																				
			Pacific Research Institute		
				
																						
			June 13, 2025		
				
					
			Commentary				
			
		Tying U.S. Drug Prices To Foreign Markets Risks Innovation And Lives
			Earlier this month, President Donald Trump signed what he called “one of the most consequential Executive Orders in our Country’s history.” The order is essentially an updated version of his administration’s 2020 “Most Favored Nation” policy. It directs pharmaceutical companies to tie the U.S. prices of their drugs to the ...		
					
					
			
																				
			Sally C. Pipes		
				
																						
			May 27, 2025		
				
					
			Commentary				
			
		Trump’s ‘Most Favored Nation’ Drug Plan Doesn’t Favor Americans
			Last week, President Donald Trump revived one of the most ill-conceived health policy ideas of his first term. Via a new executive order, he’s directed his administration to deliver “most-favored-nation prescription drug pricing to American patients.” The idea is to bring other developed countries’ lower drug prices to the United ...		
					
					
			
																				
			Sally C. Pipes		
				
																						
			May 22, 2025		
				
					
			Drug Importation				
			
		Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
			Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...		
					
					
			
																				
			Sally C. Pipes		
				
																						
			May 7, 2025		
				
					
			Blog				
			
		Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
			The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...		
					
					
			
																				
			Wayne Winegarden		
				
																						
			March 24, 2025		
				
					
			Drug Importation				
			
		Sally Pipes – The World’s Medicine Chest
			This week, we present a special presentation of our recent webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores ...		
					
					
			
																				
			Pacific Research Institute		
				
																						
			March 3, 2025		
				
					
			340B				
			
		Watch Webinar with Sally Pipes on her new book, “The World’s Medicine Chest”
			Watch the webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores how America became the world’s leader in biopharmaceutical ...		
					
					
			
																				
			Pacific Research Institute		
				
																						
			February 26, 2025		
				
					Learn How Drug Price Controls Hurt Patients
Big Pharma Is Not Gouging Americans nor Driving Up Healthcare Costs
			Whether it is Sanders vilifying pharmaceutical companies or Trump’s emphasis on imposing price controls, they both allege that drug spending is a primary driver of the nation’s rising healthcare costs. Even a cursory look at the data demonstrates their focus is misplaced. Let’s start with the national health expenditure data ...		
					Cheap Drugs from Canada Can’t Make America Healthy
			The U.S. Food and Drug Administration just announced plans to help states and Indian tribes purchase certain prescription drugs from Canada, where brand-name medicines tend to be cheaper because the government caps their price. The new guidance is part of a larger Trump administration effort to cut drug prices for ...		
					The 340B Discounts Hospitals Receive Will Often Exceed Total Drug Prices in Europe
			Table 1: PBM Fees and Rebates Can Exceed International Prescription Medicine Prices by As Much As 900% I previously highlighted how estimated rebates and fees PBMs receive for 10 commonly used brand medicines far exceed the total prices of those medicines in eight OECD countries (see Table 1). For example, ...		
					Listen to Sally Pipes on “Free the Economy” podcast
			Listen to PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes discuss her new book The World’s Medicine Chest (Encounter Books) on the Free the Economy podcast from the Competitive Enterprise Institute. Click here to listen		
					Tying U.S. Drug Prices To Foreign Markets Risks Innovation And Lives
			Earlier this month, President Donald Trump signed what he called “one of the most consequential Executive Orders in our Country’s history.” The order is essentially an updated version of his administration’s 2020 “Most Favored Nation” policy. It directs pharmaceutical companies to tie the U.S. prices of their drugs to the ...		
					Trump’s ‘Most Favored Nation’ Drug Plan Doesn’t Favor Americans
			Last week, President Donald Trump revived one of the most ill-conceived health policy ideas of his first term. Via a new executive order, he’s directed his administration to deliver “most-favored-nation prescription drug pricing to American patients.” The idea is to bring other developed countries’ lower drug prices to the United ...		
					Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
			Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...		
					Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
			The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...		
					Sally Pipes – The World’s Medicine Chest
			This week, we present a special presentation of our recent webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores ...		
					Watch Webinar with Sally Pipes on her new book, “The World’s Medicine Chest”
			Watch the webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores how America became the world’s leader in biopharmaceutical ...